A highly luminescent tetrahydrocurcumin Ir(III) complex with remarkable photoactivated anticancer activity. by Dragonetti,  Claudia et al.
Durham Research Online
Deposited in DRO:
16 April 2019
Version of attached file:
Accepted Version
Peer-review status of attached file:
Peer-reviewed
Citation for published item:
Dragonetti, Claudia and Colombo, Alessia and Fontani, Mattia and Roberto, Dominique and Williams,
Gareth and Scotto di Perrotolo, Rossella and Casagrande, Francesca and Barozzi, Sara and Polo, Simona
(2019) 'A highly luminescent tetrahydrocurcumin Ir(III) complex with remarkable photoactivated anticancer
activity.', Chemistry  a European journal., 25 (33). pp. 7948-7952.
Further information on publisher's website:
https://doi.org/10.1002/chem.201901527
Publisher's copyright statement:
This is the accepted version of the following article: Dragonetti, Claudia, Colombo, Alessia, Fontani, Mattia, Roberto,
Dominique, Williams, Gareth, Scotto di Perrotolo, Rossella, Casagrande, Francesca, Barozzi, Sara Polo, Simona
(2019). A highly luminescent tetrahydrocurcumin Ir(III) complex with remarkable photoactivated anticancer activity.
Chemistry  A European Journal 25(33): 7948-7952 which has been published in final form at
https://doi.org/10.1002/chem.201901527. This article may be used for non-commercial purposes in accordance With
Wiley Terms and Conditions for self-archiving.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
Supported by
A Journal of
Accepted Article
Title: A highly luminescent tetrahydrocurcumin Ir(III) complex with
remarkable photoactivated anticancer activity
Authors: Claudia Dragonetti, Alessia Colombo, Mattia Fontani,
Dominique Roberto, Gareth Williams, Rossella Scotto di
Perrotolo, Francesca Casagrande, Sara Barozzi, and Simona
Polo
This manuscript has been accepted after peer review and appears as an
Accepted Article online prior to editing, proofing, and formal publication
of the final Version of Record (VoR). This work is currently citable by
using the Digital Object Identifier (DOI) given below. The VoR will be
published online in Early View as soon as possible and may be different
to this Accepted Article as a result of editing. Readers should obtain
the VoR from the journal website shown below when it is published
to ensure accuracy of information. The authors are responsible for the
content of this Accepted Article.
To be cited as: Chem. Eur. J. 10.1002/chem.201901527
Link to VoR: http://dx.doi.org/10.1002/chem.201901527
FULL PAPER    
 
 
 
 
 
A highly luminescent tetrahydrocurcumin Ir(III) complex with 
remarkable photoactivated anticancer activity 
Alessia Colombo,[a] Mattia Fontani,[a] Claudia Dragonetti,[a]* Dominique Roberto,[a] J. A. Gareth 
Williams,[b]* Rossella Scotto di Perrotolo,[c] Francesca Casagrande,[c] Sara Barozzi,[c] and Simona 
Polo[c],[d]* 
Dedicated to Emeritus Professor Renato Ugo for his 81st birthday
Abstract: Curcumin has chemopreventive properties against a 
variety of tumours, but it has poor bioavailability. Two new bis-
cyclometallated iridium(III) complexes have been prepared,  
featuring the natural product curcumin (CUR) or its reduced form, 
tetrahydrocurcumin (THC), as bidentate, anionic O^O-binding 
ligands.  The iridium THC complex is highly luminescent in 
deoxygenated solution and efficiently generates singlet oxygen 
under aerated conditions, whereas in the curcumin analogue, other 
non-radiative decay pathways are competitive.  The complexes are 
rapidly taken up into a variety of human tumour cell lines from 
solutions of micromolar concentration.  They have negligible 
cytotoxicity in the absence of irradiation.  When briefly irradiated by 
visible light, Ir-THC becomes highly phototoxic, inducing rapid 
apoptosis within 2 h.  The results show the high potential of such 
complexes as sensitizers in photodynamic therapy (PDT). 
Introduction 
Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepta-
diene-3,5-dione (CUR, Fig. 1), is a polyphenolic natural 
product isolated from Curcuma longa, a rhizomatous 
herbaceous plant. CUR has been a well-recognized dietary 
spice for centuries and its pharmacological activities have 
been studied in various clinical studies including anti-
inflammatory, anti-diabetic, anti-dementia, and anti-oxidant 
properties.[1] In particular, it appears to have 
chemopreventive properties against a variety of human 
malignancies and is currently in clinical trials as an 
anticancer agent.[2] In Phase I clinical trials, it was 
concluded that humans can tolerate a CUR dose as high as 
8 g / day with no side effects.[3] However, CUR shows poor 
oral bioavailability: its concentration in human plasma and 
other tissues is extremely low even after a high oral dose.  
This is due to its instability with respect to hydrolysis of the 
β-diketone unit under physiological conditions, rapidly 
leading to species such as ferullic acid and vanillin.[4,5]  
Interestingly, binding this moiety in the deprotonated 
anionic form to a metal centre increases its hydrolytic 
stability, with respect to free curcumin, and the resulting 
complexes can show cytotoxic activity.[4,6] Indeed, a 
bioreductively-activated cobalt(III) carrier system for the 
delivery of curcumin with enhanced drug stability and 
efficacy against colon cancer cells was recently reported.[4b]  
 
 
Figure 1. The structures of curcumin (CUR), tetrahydrocurcumin (THC), and 
their corresponding iridium(III) complexes Ir-CUR and Ir-THC featuring the 
ligands in their anionic (deprotonated) forms.  
The high instability of CUR suggests that it may be the 
products of its metabolism that are responsible for its 
pharmacological effects in vivo.[7] In particular, 
tetrahydrocurcumin (THC) is one of CUR active metabolites 
(Fig. 1) and might play a crucial role in CUR-induced 
biological effects. Its easy absorption through the 
gastrointestinal tract suggests that THC might even be a 
better candidate than CUR for the development of 
anticancer agents.[8] In agreement with this observation, 
THC exhibits significant cell growth inhibition by inducing 
human breast cancer MCF-7 cells to undergo mitochondrial 
apoptosis and G2/M arrest.[8]   
The photobiological activity of curcumin is related to its 
ability to generate reactive oxygen species (ROS) which 
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lead to cancer cell death by apoptosis via mitochondrial 
pathways.[4]  Curcumin’s photochemical properties are 
therefore important in this context.[9]  It shows a strong 
absorption band around 410–430 nm and fluorescence in 
the region 460–560 nm in solution at room temperature, 
with a quantum yield in the range 0.02–0.08 according to 
the solvent. While the singlet excited state decays by a non-
radiative process, its triplet state reacts with ground-state 
3O2 to generate singlet oxygen 1O2 efficiently.  CUR is thus 
of great interest for photodynamic therapy (PDT), a 
treatment in which the cytotoxicity of a drug is selectively 
activated by light only in cancerous regions, through 
generation of 1O2, and showing promise for several types of 
solid cancer.[10, 11]    
Nevertheless, although curcumin could have potential 
as a PDT agent, its low bioavailability would severely limit 
its efficacy.  The greater stability of metal complexes of 
CUR, coupled with longer-wavelength absorption, could 
render them suitable for such phototherapeutic 
applications.[4] Surprisingly, despite growing interest in the 
use of iridium complexes as PDT agents,[11]  only one 
iridium complex incorporating curcumin as a ligand has 
been reported up to now [12]. Pettinari et al. reported that 
[Cp*Ir(curc)Cl] (in which Cp* = pentamethylcyclo-
pentadienyl, curcH= curcumin) is moderately cytotoxic to 
both human ovarian cancer cells and non-tumorigenic 
human embryonic kidney cells, though its potential as a 
PDT agent was not investigated.[12b] However, 
cyclometallated Ir(III) complexes could have great potential 
in PDT because they may efficiently generate 1O2 due to 
the presence of the heavy atom which favours a fast 
intersystem crossing to triplet states with microsecond 
lifetimes.[13] Moreover, they are often luminescent, offering 
potential for cellular imaging, and for what is known as 
theranostics – the combination of therapy and imaging.[14-27]  
Based on these observations, we decided to prepare and 
study an Ir(III) complex bearing two cyclometallated 
phenylpyridine (ppy) ligands and curcumin (Ir-CUR, Fig. 1).  
We also synthesised the related complex with 
tetrahydrocurcumin (Ir-THC, Fig. 1), whose metal 
complexes have never been reported. 
Results and Discussion 
The target Ir(III) complexes (Fig.1) resemble in 
structure those of the type [Ir(N^C)2(O^O)], where O^O is 
an anionic β-diketonate ligand of which acetylacetonate 
(acac–) is the archetypal example.[16] They were 
synthesised by reaction of [Ir(N^C-ppy)2(µ-Cl)]2 with the 
commercial curcumin or tetrahydrocurcumin proligand in 
methanol in the presence of sodium methoxide to 
deprotonate the β-diketone (Scheme S1 in the Supporting 
Information, SI). The desired products were purified by 
recrystallization from a mixture of dichloromethane and 
diethylether. The identities and purities of the products were 
confirmed by 1H and 13C NMR spectroscopy and by 
elemental analysis (details are provided in the SI). The UV-
visible spectra of the two complexes show moderately 
intense absorption bands stretching into the visible region 
due to charge-transfer transitions, along with pi−pi* bands in 
the UV region (Fig. S1, SI). Stability measurements under 
physiological conditions, both of the ligands and of the 
iridum complexes, have been performed by monitoring the 
UV-visible spectra (Fig. S2, SI). The results evidence that 
curcumine is not stable under physiological conditions, 
whereas tetrahydrocurcumin and both of the new iridium 
complexes are rather stable.  
 At room temperature, the Ir-CUR complex shows no 
detectable luminescence in deoxygenated CH2Cl2 solution. 
The lack of luminescence would be consistent with a trans-
cis isomerization of the olefinic double bond acting as a 
deactivation pathway, as previously suggested in Ir(III) 
complexes incorporating C=C-appended ligands.[28,29] It may 
also be due to the CUR ligand having low-energy pi* orbitals 
associated with it, such that the lowest-energy triplet 
excited state becomes localised on this ligand as opposed 
to it having the usual dIr / pippy → pi*ppy charge-transfer 
character that would typically lead to efficient 
phosphorescence.  Such an effect is well-established for 
Ir(III) complexes with O^O ligands featuring more extended 
conjugation, such as dibenzoylmethane, which have low-
energy ligand-based triplet-states.[30]  A similar effect has 
been observed for related platinum(II) complexes with O^O 
ligands featuring low-energy triplet states.[31] At low 
temperature (77 K), the deactivating pathway is inhibited:  
the complex emits in the red region of the spectrum, 
displaying a highly structured profile, λ(0,0) = 602 nm, and a 
lifetime of 5.9 µs (spectra are shown in Fig. S1, SI). 
In contrast, the related Ir-THC complex, which lacks 
olefinic bonds in the O^O ligand, is an extraordinarily bright 
green emitter at room temperature (λmax = 520 nm). The 
luminescence lifetime is 1.8 µs in deoxygenated CH2Cl2 
solution whilst its photoluminescence quantum yield of 0.90 
renders it one of the most brightly emitting Ir(III) complexes 
reported, comparable to that of the archetypal complex fac-
Ir(ppy)3.[32]  Assuming that the emitting state is formed with 
unitary efficiency upon light absorption, the radiative rate 
constant kr and non-radiative rate constant knr can be 
estimated from kr = Φ/τ and knr = (1–Φ)/τ. The high value of 
kr of 5 x 105 s–1 coupled with the relatively low value of 
5.5 x 104 s–1 for knr account for the bright emission. This 
contrasts strikingly with tetrahydrocurcumin itself, which is 
only very weakly emissive in ethanol solution at room 
temperature (Φ  0.007).[33] 
The intense green phosphorescence of Ir-THC in 
deoxygenated solution is strongly quenched by oxygen.  
The emission lifetime is reduced to 70 ns in air-equilibrated 
solution, from which a rough estimate of the bimolecular 
rate constant for quenching by O2 can be calculated to be 
6.2 × 109 M–1s–1.  Such quenching of transition metal 
complexes is often accompanied by formation of the excited 
1∆g state of oxygen, commonly referred to as singlet oxygen 
or 1O2.  In the present instance, the emission of the 1O2 
thereby generated could be readily detected in the near 
infrared (NIR) region (1274 nm; Fig. S1, SI). Using a 
previously described procedure[34] with perinaphthenone 
(also known as phenalenone) as the standard (Φ = 0.95[35]),  
the quantum yield of 1O2 generation was estimated to be 
0.42 in CH2Cl2.  Further details and representative plots are 
provided in the Supporting Information.  As noted above, 
there is still some phosphorescence observed in air-
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equilibrated solution, and so the singlet oxygen quantum 
yield under those conditions is somewhat lower than that of 
phosphorescence in deoxygenated solution.  The rate of 
deactivation of the Ir-THC excited state by oxygen can be 
estimated from the lifetimes to be around 1.3 x 107 s–1 in 
air-equilibrated solution which, though larger than the value 
of kr given above, still allows some phosphorescence to be 
observed.  No singlet oxygen was detected for Ir-CUR, 
probably because the rate of deactivation of its triplet state 
is too fast for it to act as a sensitiser. 
The cellular uptake of the new iridium(III) complexes 
was probed by emission microscopy. Both complexes are 
characterized by high cell permeability and fast 
internalization kinetics in A549 – a human alveolar basal 
epithelial cancer cell line – and in cervical cancer HeLa 
cells (Fig. 2a and Fig. S3, SI). While the Ir-CUR is barely 
detectable (as is the case also for controls treated with 
CUR  or THC), the emission from the cells treated with the 
Ir-THC complex is extremely bright (Fig. 2a). It is visible 
even after incubation at a dose of 0.3 µM and is localized 
inside the cells at the mitochondria, as confirmed by co-
staining experiments with MitoTracker® dyes (Fig. S3, SI). 
 
  
 
Figure 2 (a) Immunofluorescence analysis of HeLa cells incubated for 2 h with 
the indicated compounds at 30 µM concentration and co-stained with the 
nucleus-specific dye DAPI. Images were taken by confocal microscopy with an 
excitation wavelength of 495 nm. Emission from the complexes is green; DAPI 
is blue and localised to the nuclei. (b) MTT assay of A549 cells continuously 
treated for 2 days with the indicated concentrations of Ir-CUR and Ir-THC 
compounds without irradiation. DMSO indicates cells treated with 0.15% 
DMSO as for the 30 µM Ir-Cur and Ir-THC. % of cell viability of the various 
samples are not statistically different. 
 
 It is notable that the cells appear to be unaffected by 
the presence of the two complexes. This observation was 
further confirmed by an MTT assay performed at various 
concentrations of the complexes: no reduction in cell 
viability was evident, even after 48 h of continuous 
treatment at concentration of 30 µM under normal cell 
culture conditions (Fig. 2b). These results were further 
confirmed by a CCK (cell counting kit) assay (Fig. S3c, SI). 
The photocytoxicity of the Ir-THC complex was assessed 
through irradiation at different wavelengths coupled with 
time-lapse microscopy to view the effect of light on the 
cells. The cells were irradiated with a xenon lamp through 
three different excitation filters (360-370 nm, 465-495 nm 
and 530-560 nm) and for different lengths of time (0.5 s, 1 s 
and 2 s) and were subsequently monitored over a period of 
48 h. As can be seen in Figure S3, A549 cells treated with 
30 µM of Ir-THC for 2 h in the incubator, and irradiated in 
the wavelength range 465-495 nm for 2 s (at a power of 5.6 
mW mm–2), underwent apoptosis within less than 2 h. The 
use of light in the 530-560 nm region has an intermediate 
effect in initiating apoptosis, consistent with the limited 
absorption of the complexes at such long wavelengths. 
Based on the previous observations, we hypothesize that 
1O2 or related reactive oxygen species generated upon 
excitation of the compound are responsible for the observed 
phototoxicity. The contrast between the light-induced cytotoxicity 
and the lack of toxicity in the absence of light is of crucial 
importance for the design of PDT agents. 
 To compare Ir-CUR and Ir-THC and confirm the 
specificity of the cytotoxicity, we performed a series of 
experiments in which A549 cells were treated with the two 
complexes and the free pro-ligands CUR and THC at a 
concentration of 30 µM in each case (Fig. 3).  
 
   
 
 
Figure 3 Sample images of the time-lapse experiment performed on A549 
cells treated with Ir-THC for 2 h and the indicated compounds at 30 µM 
concentration before irradiation and recording.  Cells were irradiated for 2 s in 
the wavelength range 465-495 nm  (5.6 mW mm–2) and this time point is 
considered T0. 
 
The Ir-CUR complex upon irradiation showed much 
reduced activity compared to Ir-THC, an observation that is 
consistent with the earlier conclusion of rapid deactivation of the 
excited state.  It is remarkable to note that, for cells treated with 
the Ir complexes, neighbouring cells in the culture plates that 
were not subject to irradiation were perfectly viable. Free CUR 
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showed limited phototoxicity whilst free THC did not show any 
such activity at all, demonstrating the fundamental role played 
by the coordination to the iridium(III) center for the phototoxicity. 
Subsequent experiments were conducted with Ir-THC at a range 
of lower concentrations. Results indicated that a dose of 10 µM 
is sufficient to kill all the treated cells when irradiated for 2 s (Fig. 
4a). In order to assess the broader applicability to other cell 
lines, analogous phototoxicity experiments have been carried 
out on HeLa cells and human brain glioblastoma T89G cells, 
treated with 4 and 8 µM of Ir-THC. No evident differences are 
visible among the various cell lines, though A549 cells appear to 
be more resistant at 4 µM concentration (Fig. 4b). 
 
 
Figure 4 (a) Sample images of the time-lapse experiment performed on A549 
cells treated with Ir-THC at the concentrations indicated. Circles underline the 
irradiated region of the wells.   (b) Comparison of images obtained at 1 and 
24 h treatment of A549, HeLa and T89G cells at 4 and 8 µM. Cells were 
irradiated for 2 s in the wavelength range 465-495 nm (5.6 mW mm–2). 
 
 
The LD50 (half lethal dose concentration) of the Ir-THC 
complex was calculated with the set parameters (2 h pre-
incubation, 465-495 nm, 2 s irradiation) using the CCK assay in 
HeLa and A549. Ir-THC gave LD50 values of 5-7 µM.  We also 
tested the effect of longer irradiation of cells treated with a lower 
concentration of complex. Strikingly, phototoxicity is visible even 
with 1 µM of Ir-THC, when cells are irradiated for 20 s (Fig S5, 
SI). These results are exceptionally promising for photodynamic 
therapy, since the phototoxicity index (PI) of the complexes is 
remarkably high (>200) and the time of light exposure is very 
low. 
 
Conclusions 
In conclusion, the new cyclometallated Ir(III) complex with a 
tetrahydrocurcumin ligand, Ir-THC, appears to be a very 
promising tool for combined photodynamic therapy and 
cellular imaging.  It has several desirable properties for the 
purpose: (i) it is highly phosphorescent and soluble; (ii) it 
easily enters into cells where it is concentrated in 
mitochondria, even at limited concentration; (iii) it is highly 
phototoxic upon irradiation with suitable light, but not 
cytotoxic in the dark. These results highlight how 
photoactive metal complexes of curcuminoids may offer 
interesting future potential for phototherapeutic applications 
in combination with emission imaging microscopy. 
Experimental Section 
Experimental details are in the available Supporting Information: 
synthesis and NMR spectra, absorption and emission spectra of 
the Ir(III) complexes, cell lines, cellular uptake and staining, time 
lapse experiments, cell viability (MTT and CCK) assays. 
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